Antibody Engineering Cuts the Collateral Damage of Cancer Drugs

Killing cancer cells, while leaving normal tissue unscathed, is almost impossible. Nanotechnology may do the trick, but big pharmaceutical companies are far from embracing that strategy. In the meantime, highly-engineered biological molecules will fill the void. Antibodies can recognize cancer cells, and latch onto them, but they won’t kill their targets without some help. By attaching powerful poisons [...]